Azitra (AZTR) Research & Development (2022 - 2026)
Azitra (AZTR) reported Research & Development of $1.6 million for Q1 2026, up 24.84% on a YoY basis from $1.3 million in Q1 2025, and up 55.44% quarter-over-quarter from $1.0 million in Q4 2025.
Azitra (AZTR) Research & Development (2022 - 2026) Analysis & Trends
Azitra has reported Research & Development for 5 years, with the latest figure at $1.6 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 24.84% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (up 14.35% YoY), and the FY2025 full-year result was $4.8 million, up 2.38% from the prior year.
- Research & Development for Q1 2026 stood at $1.6 million, up from $1.0 million in the prior quarter.
- The five-year high for Research & Development was $1.7 million in Q4 2022, with the low at $548524.0 in Q3 2023.
- Historically, Research & Development has averaged $1.2 million across 5 years, with a median of $1.2 million in 2025.
- Annual changes were most pronounced in 2023 — Research & Development plunged 59.8% — and 2024, when it surged 85.19%.
- Azitra's Research & Development stood at $1.7 million in 2022, then declined by 9.69% to $1.5 million in 2023, then declined by 26.12% to $1.1 million in 2024, then retreated by 10.04% to $1.0 million in 2025, then soared by 55.44% to $1.6 million in 2026.
- The last three Research & Development figures came in at $1.6 million (Q1 2026), $1.0 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 1.51 Mn |
| Sep 30, 2023 | 548,524.00 |
| Jun 30, 2023 | 754,951.00 |
| Mar 31, 2023 | 829,035.00 |
| Dec 31, 2022 | 1.67 Mn |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 1.51 Mn |